Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans
- PMID: 10600919
- DOI: 10.1152/ajpregu.1999.277.6.R1718
Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans
Abstract
Intraduodenal fat inhibits gastric emptying and exerts early satiation in animals and humans, but it is not clear whether the effects are mediated by cholecystokinin (CCK) in humans. Here, we tested whether CCK-A receptors mediate the inhibition of fat on food intake. Two sequential, double-blind, crossover studies were performed in 24 male subjects. First, subjects received either intraduodenal fat or saline together with a preload of either water or banana shake. Second, 12 subjects received either intraduodenal fat or saline perfusion plus a concomitant infusion of saline or loxiglumide, a specific CCK-A receptor antagonist, together with a preload of banana shake. In both studies, subjects were free to eat and drink as much as they wished. Fat induced a reduction in calorie intake (P < 0.05) compared with controls. Furthermore, a decrease in hunger feelings was observed. Infusion of loxiglumide abolished the effects of fat. Duodenal fat interacts with an appetizer to modulate energy intake in humans. This effect is mediated by CCK-A receptors.
Similar articles
-
The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans.Gut. 2000 May;46(5):688-693. doi: 10.1136/gut.46.5.689. Gut. 2000. PMID: 10764713 Free PMC article. Clinical Trial.
-
Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.Am J Physiol Regul Integr Comp Physiol. 2001 Apr;280(4):R1149-54. doi: 10.1152/ajpregu.2001.280.4.R1149. Am J Physiol Regul Integr Comp Physiol. 2001. PMID: 11247838
-
Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.Gut. 1994 Apr;35(4):501-5. doi: 10.1136/gut.35.4.501. Gut. 1994. PMID: 8174988 Free PMC article. Clinical Trial.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Role of cholecystokinin in appetite control and body weight regulation.Obes Rev. 2005 Nov;6(4):297-306. doi: 10.1111/j.1467-789X.2005.00212.x. Obes Rev. 2005. PMID: 16246215 Review.
Cited by
-
Gastrointestinal peptides in eating-related disorders.Physiol Behav. 2021 Sep 1;238:113456. doi: 10.1016/j.physbeh.2021.113456. Epub 2021 May 11. Physiol Behav. 2021. PMID: 33989649 Free PMC article. Review.
-
CCK(1) receptor is essential for normal meal patterning in mice fed high fat diet.Physiol Behav. 2007 Dec 5;92(5):969-74. doi: 10.1016/j.physbeh.2007.07.003. Physiol Behav. 2007. PMID: 18023701 Free PMC article.
-
Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications.Nutrients. 2021 Apr 1;13(4):1158. doi: 10.3390/nu13041158. Nutrients. 2021. PMID: 33915747 Free PMC article. Review.
-
Enteroendocrine cells: neglected players in gastrointestinal disorders?Therap Adv Gastroenterol. 2008 Jul;1(1):51-60. doi: 10.1177/1756283X08093943. Therap Adv Gastroenterol. 2008. PMID: 21180514 Free PMC article.
-
Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Physiol Rev. 2017 Jan;97(1):411-463. doi: 10.1152/physrev.00031.2014. Physiol Rev. 2017. PMID: 28003328 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical